Welcome to our dedicated page for BeOne Medicines Ltd. news (Ticker: ONC), a resource for investors and traders seeking the latest updates and insights on BeOne Medicines Ltd. stock.
BeOne Medicines Ltd. (ONC) generates a steady flow of oncology news that reflects its focus on hematology and solid tumors. As a Switzerland‑domiciled global oncology company with listings on NASDAQ, the Hong Kong Stock Exchange and the STAR Market in Shanghai, BeOne regularly issues updates on clinical data, regulatory milestones, financial performance and corporate developments.
Investors and healthcare professionals following ONC news will see frequent announcements related to B‑cell malignancies, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The company highlights new data for its BTK inhibitor BRUKINSA, including long‑term results from Phase 3 trials such as SEQUOIA and ALPINE, as well as patient‑reported outcomes and guideline updates. News also covers sonrotoclax, an investigational BCL2 inhibitor, with items on FDA Breakthrough Therapy Designation, Priority Review for relapsed or refractory MCL, and clinical results in CLL and other B‑cell cancers. Updates on BTK degrader BGB‑16673 from the CaDAnCe clinical program appear alongside these hematology releases.
On the solid tumor side, BeOne’s news includes Phase 3 trial results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2‑positive gastroesophageal adenocarcinoma, as well as regulatory plans based on these data. Additional releases describe TEVIMBRA’s expanding indications and BGB‑B2033’s FDA Fast Track Designation in hepatocellular carcinoma. Financial news items provide quarterly revenue, product sales trends for BRUKINSA and TEVIMBRA, cash flow metrics and updated guidance, while corporate updates cover conference presentations, research milestones and agreements such as the IMDELLTRA royalty purchase arrangement with Royalty Pharma.
For users tracking ONC, this news stream offers insight into BeOne’s evolving hematology and solid tumor portfolios, its regulatory interactions in major markets and its stated goal of broadening patient access to cancer therapies. Bookmarking the ONC news page on Stock Titan allows readers to follow company press releases, clinical milestones and financial disclosures in one place.
Two rapid oral presentations featuring BRUKINSA® (zanubrutinib) data from the SEQUOIA trial in chronic lymphocytic leukemia (CLL), including: - Long-term follow-up results from Arm C in treatment-naïve CLL patients with del(17p) mutations - First results from Arm D evaluating BRUKINSA plus venetoclax combination therapy
The company will present early-phase data for novel breast cancer treatments: - BG-C9074: A B7-H4-targeting antibody-drug conjugate for advanced solid tumors - BG-68501: A CDK2 inhibitor for HR+/HER2- breast cancer - TEVIMBRA®: Final analysis showing promising efficacy in esophageal squamous cell carcinoma
The presentations demonstrate BeiGene's commitment to advancing cancer treatment across multiple fronts, from hematologic malignancies to solid tumors.
BeiGene (NASDAQ: ONC), a global oncology company, has announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The company, which will be renamed to BeOne Medicines Ltd., will engage in a fireside chat on May 20, 2025, at 10 a.m. EDT. Investors can access the live webcast through the company's investor relations websites, and an archived replay will remain available for one year after the event.
BeiGene has secured a significant legal victory as the U.S. Patent and Trademark Office (USPTO) invalidated all challenged claims of Pharmacyclics' Patent No. 11,672,803. This ruling comes in response to BeiGene's post-grant review petition filed on November 1, 2023, following Pharmacyclics' patent infringement lawsuit regarding BRUKINSA (zanubrutinib).
The USPTO's Final Written Decision, while appealable by Pharmacyclics, supports BeiGene's position that the '803 patent was overly broad and invalid. BRUKINSA, BeiGene's independently developed medicine for B-cell malignancies, has received approvals in over 70 countries and regions.
BeiGene, which plans to change its name to BeOne Medicines, maintains confidence in their intellectual property rights supporting BRUKINSA, which continues to establish new standards in patient care worldwide.